Form 4: Aclaris Therapeutics Director Maxine Gowen Reports Stock Unit Vesting
SEC Form 4 Filing
Director Maxine Gowen reports the vesting of 4,660 restricted stock units convertible to common stock in Aclaris Therapeutics.
Summary
- Maxine Gowen, a director of Aclaris Therapeutics, Inc., reported the vesting of 4,660 restricted stock units on June 1, 2024.
- These units convert to 4,660 shares of common stock.
- Following the transaction, Ms. Gowen directly owns 16,961 shares of Aclaris Therapeutics.
- Ms. Gowen has granted power of attorney to Kevin Balthaser, Matthew Rothman, Mark Ballantyne, David Brinton, and Robin Lee to handle SEC filings related to her holdings.
Sentiment
Score: 5
Explanation: This is a routine disclosure of stock unit vesting, which is neither particularly positive nor negative. It's a neutral event in terms of investment sentiment.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders, such as directors and officers, ensuring fair market practices.
Stakeholder Impact
- The vesting of stock units may have a minor dilutive effect on existing shareholders.
Key Dates
| Date | Description |
|---|---|
| 05/16/2024 | Date of Power of Attorney execution by Maxine Gowen |
| 06/01/2024 | Date of transaction: Vesting of restricted stock units |
| 06/04/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.